Skip to content
Review

Abstract 5228: Circulating MicroRNAs versus Cardiac Troponins for Predicting Cardiotoxicity in Adult Cancer Patients Treated with Anthracyclines: A Systematic Review and Meta-Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Anthracycline-induced cardiotoxicity is a major limitation in cancer treatment, potentially leading to cardiac dysfunction and heart failure. Early detection of cardiotoxicity is essential to improve outcomes. Although cardiac troponins are widely used, their predictive performance remains suboptimal. Circulating microRNAs have emerged as promising early biomarkers; however, their comparative clinical value remains uncertain. Objective: This systematic review and meta-analysis aims to evaluate and compare the predictive performance of circulating microRNAs and cardiac troponins for anthracycline-induced cardiotoxicity. Methods: A systematic review and meta-analysis were conducted according to PRISMA guidelines. PubMed, Embase, and Cochrane Library were searched from inception to November 1, 2025. Observational studies comparing circulating microRNAs and cardiac troponins for prediction of anthracycline-induced cardiotoxicity in adult cancer patients were included. Cardiotoxicity was defined as clinical heart failure or subclinical decline in left ventricular ejection fraction (LVEF). Random-effects generalized linear mixed models were used to estimate pooled detection proportions. Comparative analyses included risk difference (RD) and risk ratio (RR) with Hartung-Knapp adjustment. Secondary meta-regression analyses evaluated the effects of age and cumulative anthracycline dose on cardiotoxicity heterogeneity. Results: Four comparative studies involving 536 patients were included in the pooled analysis. Circulating miRNAs demonstrated a numerically higher pooled proportion of cardiotoxicity prediction than cardiac troponins (0.12 [95% CI: 0.07-0.20] vs. 0.02 [95% CI: 0.00-0.21]) (Figure 1). However, direct comparative analyses did not reach statistical significance after Hartung-Knapp adjustment (RR=2.38 [95% CI: 0.21-27.09]; RD=0.08 [95% CI: -0.08 to 0.23]) (Figure 2). Meta-regression identified age as a significant moderator of cardiotoxicity risk, explaining 52.1% of between-study heterogeneity (p=0.026), whereas cumulative anthracycline dose showed no significant association (p=0.927) (Figure 3). Conclusions: Circulating miRNAs showed higher cardiotoxicity prediction rates than cardiac troponins, supporting their potential as early biomarkers of anthracycline-induced cardiotoxicity. Although pooled comparisons were not statistically significant, age significantly influenced cardiotoxicity risk. Larger prospective studies are needed to validate miRNA-guided surveillance. Keywords: Anthracycline-induced cardiotoxicity; MicroRNAs; Cardiac troponins

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.